publication . Article . 2020

Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure

Laura Lorenzo-Soler; Olof Birna Olafsdottir; Gerhard Garhöfer; Phatsawee Jansook; Iris Myrdal Kristinsdottir; Aimin Tan; Thorsteinn Loftsson; Einar Stefánsson;
Open Access English
  • Published: 16 Nov 2020 Journal: Acta Ophthalmologica (issn: 1755-375X, eissn: 1755-3768, Copyright policy)
PURPOSE Orally administered angiotensin II receptor blockers (ARBs) decrease intraocular pressure (IOP). Topical administration may reduce systemic side effects and result in a useful glaucoma drug. The aim of this study is to test the ocular delivery and pharmacologic effect of nanoparticle eye drops containing ARBs (e.g. irbesartan and candesartan). METHODS 1.5% irbesartan and 0.15% candesartan eye drops were applied to rabbits. The pharmacokinetics in cornea and aqueous humour after single eye drop application were studied in 49 rabbits. The effect of the eye drops on IOP was studied in 10 rabbits using an iCare (® TonoVet Plus, iCare, Finland) tonometer and ...
Persistent Identifiers
Medical Subject Headings: genetic structureseye diseasessense organs
free text keywords: angiotensin receptor blockers, intraocular pressure, cyclodextrins, pharmacokinetics, Ophthalmology, General Medicine, Ophthalmology, medicine.medical_specialty, medicine, business.industry, business, Eye drop, medicine.medical_treatment, Intraocular pressure, Timolol, medicine.drug, Irbesartan, Aqueous humour, Candesartan, Glaucoma, medicine.disease, Angiotensin receptor
Funded by
EC| transMed
Educating the next generation of scientists in translational medicine: Focus on eye diseases
  • Funder: European Commission (EC)
  • Project Code: 765441
  • Funding stream: H2020 | MSCA-ITN-ETN
Validated by funder
Any information missing or wrong?Report an Issue